Roosendaal G - Search Results

1

Hepatitis G virus RNA and hepatitis G virus-E2 antibodies in Dutch hemophilia patients in relation to transfusion history.

Mauser-Bunschoten EP, Damen M, Zaaijer HL, Sjerps M, Roosendaal G, Lelie PN, Cuypers HT, van den Berg HM. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. Blood. 1998 Sep 15;92(6):2164-8. Blood. 1998. PMID: 9731076 Free article.

2

The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia.

Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, de Kleijn P, Grobbee DE, van den Berg M. Fischer K, et al. Among authors: roosendaal g. Blood. 2002 Apr 1;99(7):2337-41. doi: 10.1182/blood.v99.7.2337. Blood. 2002. PMID: 11895765 Free article.

3

Hepatitis C infection and viremia in Dutch hemophilia patients.

Mauser-Bunschoten EP, Bresters D, van Drimmelen AA, Roosendaal G, Cuypers HT, Reesink HW, van der Poel CL, van den Berg HM, Lelie PN. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. J Med Virol. 1995 Mar;45(3):241-6. doi: 10.1002/jmv.1890450302. J Med Virol. 1995. PMID: 7539831

4

Low-dose immune tolerance induction in hemophilia A patients with inhibitors.

Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. Blood. 1995 Aug 1;86(3):983-8. Blood. 1995. PMID: 7620189 Free article.

5

Sexual transmission of hepatitis C virus.

Bresters D, Mauser-Bunschoten EP, Reesink HW, Roosendaal G, van der Poel CL, Chamuleau RA, Jansen PL, Weegink CJ, Cuypers HT, Lelie PN, et al. Bresters D, et al. Among authors: roosendaal g. Lancet. 1993 Jul 24;342(8865):210-1. doi: 10.1016/0140-6736(93)92300-i. Lancet. 1993. PMID: 8100931

6

Risk of hepatitis A in Dutch hemophilia patients.

Mauser-Bunschoten EP, Zaaijer HL, van Drimmelen AA, van den Berg HM, Roosendaal G, Lelie PN. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. Thromb Haemost. 1995 Aug;74(2):616-8. Thromb Haemost. 1995. PMID: 8584994

7

Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C.

Mauser-Bunschoten EP, Damen M, Reesink HW, Roosendaal G, Chamuleau RA, van den Berg HM. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. Ann Intern Med. 1996 Aug 15;125(4):297-9. doi: 10.7326/0003-4819-125-4-199608150-00007. Ann Intern Med. 1996. PMID: 8678393 Clinical Trial.

8

High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients.

Mauser-Bunschoten EP, Zaaijer HL, van Drimmelen AA, de Vries S, Roosendaal G, van den Berg HM, Lelie PN. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. Vox Sang. 1998;74(4):225-7. Vox Sang. 1998. PMID: 9691402 Clinical Trial.

9

Successful treatment of severe bleeding in hemophilic target joints by selective angiographic embolization.

Mauser-Bunschoten EP, Zijl JA, Mali W, van Rinsum AC, van den Berg HM, Roosendaal G. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. Blood. 2005 Apr 1;105(7):2654-7. doi: 10.1182/blood-2004-06-2063. Epub 2004 Dec 21. Blood. 2005. PMID: 15613551 Free article.

10

Factor VIII half-life and clinical phenotype of severe hemophilia A.

van Dijk K, van der Bom JG, Lenting PJ, de Groot PG, Mauser-Bunschoten EP, Roosendaal G, Grobbee DE, van den Berg HM. van Dijk K, et al. Among authors: roosendaal g. Haematologica. 2005 Apr;90(4):494-8. Haematologica. 2005. PMID: 15820945

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

95 results

Search Page